A

ANI Pharmaceuticals
D

ANIP

56.810
USD
1.02
(1.83%)
Market Closed
Volume
6,275
EPS
4
Div Yield
-
P/E
-121
Market Cap
1,194,019,798
OverviewSignalsIdeasNews
Related Instruments
    C
    CAH
    -2.540
    (-2.09%)
    118.790 USD
    H
    HSIC
    2.227
    (3.35%)
    68.777 USD
    I
    ICLR
    -10.520
    (-5.26%)
    189.600 USD
    IDXX
    IDXX
    -2.54
    (-0.60%)
    421.30 USD
    L
    LH
    -3.029
    (-1.27%)
    235.180 USD
    P
    PAHC
    -0.425
    (-1.71%)
    24.450 USD
    P
    PETQ
    0.000
    (0.00%)
    30.990 USD
    P
    PRGO
    -0.140
    (-0.52%)
    26.800 USD
    Z
    ZBH
    3.638
    (3.34%)
    112.490 USD
    ZTS
    ZTS
    0.485
    (0.28%)
    175.115 USD
    More
News

Title: ANI Pharmaceuticals

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.